Product Reports Resources Pricing Login Book a demo

Deciphera Pharmaceuticals

Biotech & Life Sciences · Waltham, United States · Founded 2003 · IPO 2017

A clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies MoreLess

Deciphera Pharmaceuticals, a member of ONO Group, is a biopharmaceutical company dedicated to discovering, developing, and commercializing new medicines aimed at improving the lives of cancer patients. The company leverages its proprietary switch-control kinase inhibitor platform and extensive expertise in kinase biology to create a broad portfolio of targeted therapies. Deciphera primarily serves the oncology market, focusing on patients with various forms of cancer. The business model revolves around the research and development of novel drugs, followed by clinical trials and regulatory approvals, leading to commercialization. Revenue is generated through the sale of these approved medicines and potential partnerships or licensing agreements with other pharmaceutical companies.

Keywords: biopharmaceutical, cancer, kinase inhibitors, oncology, drug development, clinical trials, commercialization, kinase biology, proprietary platform, oncology market.

Valuation $1.97B
Revenue $170M
Total funding $100–500M

Talent graph

Deciphera Pharmaceuticals's talent

Book a demo to see the people
Employees mapped 545 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Deciphera Pharmaceuticals's cap table

Sourced from Dealroom's funding and investor records.

Series A 2 investors entered at this stage
New Leaf Venture Partners
SV Health Investors
Series B+ 6 investors entered at this stage
Viking Global Investors
Redmile Group
Sphera Funds Management
Sphera Global Healthcare Fund
Deciphera Pharmaceuticals
Sunesis Advisors

Global footprint

Where Deciphera Pharmaceuticals has talent and traffic

Workforce by country
10 countries with
team presence
🇺🇸 United States83.8%
🇨🇭 Switzerland5.2%
🇩🇪 Germany3.4%
🇫🇷 France2%
🇪🇸 Spain1.2%
Top 5 of 10 shown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States79.4%
🇨🇦 Canada7.5%
🇮🇳 India5%
🇯🇵 Japan3.8%
🇬🇧 United Kingdom3.1%
Top 5 markets shown

Patent intelligence

Deciphera Pharmaceuticals’s patent portfolio

Estimated portfolio value
$135M

111 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Market sentiment

What the market is saying about Deciphera Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Deciphera Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Deciphera Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.